The Chong Kun Dang’s extremely obese treatment has been confirmed effectiveness through clinical trials in the U.S.
.jpg)
Chong Kun Dang (CEO Jung-woo Kim)confirmed effectiveness of the extremely obese treatment ‘CKD-732’, which has recently got on a Phase 3 clinical trialfor the Prader-Willi Syndrome, on a new obese disorder.
Zafgen, having joint research and development of CKD-732 (generic name: beloranib) with C...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
